{"id":47158,"date":"2022-08-10T18:02:05","date_gmt":"2022-08-10T16:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/"},"modified":"2022-08-10T18:02:05","modified_gmt":"2022-08-10T16:02:05","slug":"biogennix-reports-record-quarter-and-half-year-sales","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/","title":{"rendered":"Biogennix Reports Record Quarter and Half-Year Sales"},"content":{"rendered":"
\n

\nBone Regeneration Company Sets Multiple Sales Record Marks Despite Challenging Market Conditions<\/i>\n<\/p>\n

IRVINE, Calif.–(BUSINESS WIRE)–#biogennix<\/a>–Irvine-based Biogennix<\/a>, a market leader in advanced bone regeneration technology, announced today that the second quarter of 2022 was the best in company history. The company also announced that the first half of 2022 (encompassing the first and second quarters of 2022) was the best performing six-month period for the company to date.\n<\/p>\n

\n\u201cThanks to a positive reception for our more recent offerings like the DirectCell Advanced Bone Grafting System<\/a> and Agilon advanced synthetic bone graft products<\/a>, in addition to continued strong sales of our legacy bone graft products<\/a>, Biogennix is ahead of pace to once again achieve our best sales year in company history,\u201d said Chris MacDuff, Biogennix\u2019s CEO. \u201cBoth our DirectCell System and Agilon Moldable product lines have grown over 20% quarter over quarter this year, and sales have more than tripled for both when compared to the first half of 2021. It is rewarding to have achieved this sales growth during challenging market conditions.\u201d\n<\/p>\n

\nBiogennix continues to see particularly strong growth within the foot & ankle surgery market, especially with the DirectCell System and Agilon Moldable products. Both have rapidly gained popularity among surgical podiatrists who are drawn to the excellent handling<\/a> and the cell-stimulating surface technology<\/a> of Agilon, and the ability to harvest autologous stem cells without the need to centrifuge when using the DirectCell System. Biogennix also continues to achieve strong numbers in the spine and general orthopedic market segments, where the company has historically made the most impact.\n<\/p>\n

\nBiogennix CTO, Mark Borden, Ph.D., alluded to future offerings, adding, \u201cExpanding on Biogennix\u2019s expertise in advanced bone graft technologies, we have established a strong development pipeline and are focused on launching a variety of innovative solutions. We are looking forward to further growth in the second half of this year and into 2023.\u201d\n<\/p>\n

\nBiogennix\u2019s proprietary TrelCor technology is a bioactive synthetic material<\/a> engineered to jumpstart patients\u2019 natural healing processes at the cellular level. TrelCor technology uniquely combines multiple cutting-edge scientific principles into one advanced material that actively promotes cellular healing and new bone formation.\n<\/p>\n

\nBiogennix designs, manufactures and distributes all of its products from its Irvine facilities.\n<\/p>\n

\nBiogennix\u00ae<\/sup> is a market leader in advanced bone regeneration technologies. Biogennix is headquartered in Irvine, CA where they develop, manufacture, and distribute proprietary technologies used in bone fusion procedures. Biogennix team members are experts in bone graft science who are focused on creating solutions that keep distributors and surgeons on the forefront of bone regeneration. Learn more at <\/i>biogennix.com<\/i><\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPaul Williams, 310-569-0023, paul@medialinecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Bone Regeneration Company Sets Multiple Sales Record Marks Despite Challenging Market Conditions IRVINE, Calif.–(BUSINESS WIRE)–#biogennix–Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced today that the second quarter of 2022 was the best in company history. The company also announced that the first half of 2022 (encompassing the first and second quarters of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47158","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiogennix Reports Record Quarter and Half-Year Sales - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogennix Reports Record Quarter and Half-Year Sales - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Bone Regeneration Company Sets Multiple Sales Record Marks Despite Challenging Market Conditions IRVINE, Calif.–(BUSINESS WIRE)–#biogennix–Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced today that the second quarter of 2022 was the best in company history. The company also announced that the first half of 2022 (encompassing the first and second quarters of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-10T16:02:05+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biogennix Reports Record Quarter and Half-Year Sales\",\"datePublished\":\"2022-08-10T16:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/\"},\"wordCount\":442,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/\",\"name\":\"Biogennix Reports Record Quarter and Half-Year Sales - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-08-10T16:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biogennix-reports-record-quarter-and-half-year-sales\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogennix Reports Record Quarter and Half-Year Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogennix Reports Record Quarter and Half-Year Sales - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/","og_locale":"en_US","og_type":"article","og_title":"Biogennix Reports Record Quarter and Half-Year Sales - Pharma Trend","og_description":"Bone Regeneration Company Sets Multiple Sales Record Marks Despite Challenging Market Conditions IRVINE, Calif.–(BUSINESS WIRE)–#biogennix–Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced today that the second quarter of 2022 was the best in company history. The company also announced that the first half of 2022 (encompassing the first and second quarters of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-10T16:02:05+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biogennix Reports Record Quarter and Half-Year Sales","datePublished":"2022-08-10T16:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/"},"wordCount":442,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/","url":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/","name":"Biogennix Reports Record Quarter and Half-Year Sales - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-08-10T16:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biogennix-reports-record-quarter-and-half-year-sales\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biogennix Reports Record Quarter and Half-Year Sales"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47158"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47158\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}